# Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs

> **NCT02866565** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 45 (estimated)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DRUG:** adipose-derived regenerative cells (ADRCs)

## Key facts

- **NCT ID:** NCT02866565
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-06
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02866565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02866565, "Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02866565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*